312 related articles for article (PubMed ID: 18322186)
1. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
[TBL] [Abstract][Full Text] [Related]
2. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
[TBL] [Abstract][Full Text] [Related]
3. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
5. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.
Conroy H; Marshall NA; Mills KH
Oncogene; 2008 Jan; 27(2):168-80. PubMed ID: 18176598
[TBL] [Abstract][Full Text] [Related]
6. Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells.
Hickey FB; Brereton CF; Mills KH
J Leukoc Biol; 2008 Jul; 84(1):234-43. PubMed ID: 18401006
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.
Amos SM; Pegram HJ; Westwood JA; John LB; Devaud C; Clarke CJ; Restifo NP; Smyth MJ; Darcy PK; Kershaw MH
Cancer Immunol Immunother; 2011 May; 60(5):671-83. PubMed ID: 21327636
[TBL] [Abstract][Full Text] [Related]
9. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.
Hou W; Wu Y; Sun S; Shi M; Sun Y; Yang C; Pei G; Gu Y; Zhong C; Sun B
J Immunol; 2003 Feb; 170(4):1728-36. PubMed ID: 12574336
[TBL] [Abstract][Full Text] [Related]
10. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
[TBL] [Abstract][Full Text] [Related]
11. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
13. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells.
Dillon S; Agrawal A; Van Dyke T; Landreth G; McCauley L; Koh A; Maliszewski C; Akira S; Pulendran B
J Immunol; 2004 Apr; 172(8):4733-43. PubMed ID: 15067049
[TBL] [Abstract][Full Text] [Related]
14. Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation.
Lavelle EC; McNeela E; Armstrong ME; Leavy O; Higgins SC; Mills KH
J Immunol; 2003 Sep; 171(5):2384-92. PubMed ID: 12928385
[TBL] [Abstract][Full Text] [Related]
15. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype.
Flohé SB; Brüggemann J; Lendemans S; Nikulina M; Meierhoff G; Flohé S; Kolb H
J Immunol; 2003 Mar; 170(5):2340-8. PubMed ID: 12594256
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines.
Mitchell D; Yong M; Raju J; Willemsen N; Black M; Trent A; Tirrell M; Olive C
Hum Vaccin; 2011; 7 Suppl():85-93. PubMed ID: 21245658
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
18. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
19. Imiquimod enhances the potency of an exogenous BM-DC based vaccine against mouse melanoma.
Ren S; Wang Q; Zhang Y; Song Y; Dong X; Zhang W; Qin X; Liu M; Yu T
Int Immunopharmacol; 2018 Nov; 64():69-77. PubMed ID: 30149266
[TBL] [Abstract][Full Text] [Related]
20. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
Conroy H; Galvin KC; Higgins SC; Mills KH
Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
